Tenderwize
Back to tender search

Non-exclusive Drug Discount Agreement for Filgrastim

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen·Dresden, Germany·Deadline Apr 30, 2028 · 570 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Filgrastim (ATC-Code nach WHO: L03AA02)

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

40 / 100

Complexity

30 / 100

Risk factors

No guaranteed minimum purchase; actual demand depends on prescribing behavior and patient numbers, making revenue highl...

The buyer may terminate the Open-House early if exclusive discount agreements are concluded, which historically occurs...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Apr 30, 2028

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Supply of Filgrastim (ATC L03AA02) pharmaceutical products to AOK PLUS for insured persons in Saxony and Thuringia.
  • Non-exclusive discount agreements under §130a Abs. 8 SGB V.
Show full summary

This is a non-exclusive drug discount agreement (Rabattvereinbarung) for the active substance Filgrastim (ATC L03AA02) under §130a Abs. 8 SGB V, using an Open-House model. The buyer is AOK PLUS for the regions of Saxony and Thuringia, Germany. The agreement runs until 30 April 2028, with continuous enrollment. No estimated value or award criteria are provided. The procedure is not a classic public procurement but a voluntary transparency measure. Key risks include no guaranteed volume, strict confidentiality, potential early termination if exclusive agreements are concluded, and the requirement to access procurement documents via a restricted portal.

Risks

No guaranteed minimum purchase; actual demand depends on prescribing behavior and patient numbers, making revenue highl...

The buyer may terminate the Open-House early if exclusive discount agreements are concluded, which historically occurs...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as per §4 Abs. 18 AMG.
  • Company seat must be in Germany, EU, or EEA.

Eligibility

  • No grounds for exclusion under §§123, 124 GWB.

Requirements may be incomplete.

Buyer

Location

Dresden, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive Drug Discount Agreement for Filgrastim

Open-House model for non-exclusive discount agreements on Filgrastim (ATC L03AA02). The agreement covers supply of pharmaceutical products for the regions of Saxony and Thuringia. No minimum volume is guaranteed. The contract ends 30 April 2028.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Apr 2026 - Apr 2028

Category

Pharmaceutical products

Deadline

Deadline Apr 30, 2028

Procurement Details

Publication date
25 Feb 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
135009-2026

Documents (1)

Procurement document 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30